Fresenius Medical Care’s third-quarter revenue and earnings were broadly stable, with Care Delivery growth partly offset by lower Value-Based Care revenue and anticipated TDAPA reimbursement headwinds. The shares rose 2.6% after the report, a roughly flat reaction under the stated threshold.
- Management characterized revenue and earnings as broadly stable; the transcript excerpt provides no detailed financial figures.
- Organic growth in Care Delivery was partly offset by an anticipated decline in Value-Based Care revenue.
- By the end of September, 348 U.S. clinics—14% of clinics—had been converted for the 5008X rollout, with approximately 9,000 machines installed, or 16% of the install base. Management said it was on track to convert 20% of the install base by year-end.
- The company had delivered around 300,000 HV-HDF treatments in the first nine months, about 1.3% of total treatments; management said activity accelerated materially through October.
- The company had bought back 3.4% of its share capital by the end of September under its second €1 billion share-buyback program. FDA audit findings remain a focus, with corrective and preventive actions underway.
Community Discussion